Bayer Aktiengesellschaft

Bayer Aktiengellschaft

Michael L&ouml;gers

Carsten Schmeck

J&uuml;rgen Stoltefuss

Hilmar Bischoff

Delf Schmidt

Gunter Schmidt

Klaus-Dieter Bremm

Arndt Brandes

Paul Naab

Holger Paulsen

Martin Bechem

Joachim Schuhmacher

Rolf Angerbauer

Klemens Lustig

Christoph Gerdes

Stefan Antons

Michael Sperzel

Henry Giera

Ulrich Nielsch

Michael Conrad

Gabriele Br&auml;unlich

Stephan Nicholas M&uuml;ller

Werner St&uuml;rmer

Matthias M&uuml;ller-Gliemann

Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof

Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.

Substituted tetrahydronaphthaline and analogous compounds

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments. for the treatment of arteriosclerosis and dyslipidaemias.

4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hypertipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

Growing community of inventors

Wuppertal, Germany

Michael Lögers

Growing community of inventors

Wuppertal, Germany

Michael L&ouml;gers

Michael Lögers